



PATENT
NEW ATTORNEY DOCKET: 544332000121
OLD ATTORNEY DOCKET: 38626.0008

165/23
\$113
7/22/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application Of:

Michael Z. Martin, et al.

Application Number: 09/578,849

Filed: May 26, 2000

For: Pharmaceutical Preparations of
Bioactive Substances Extracted
From Natural Sources

)
)
) Group Art Unit: 1651

)
) Examiner: F.C. Prats
)
)

RECEIVED

JUL 21 2003

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants are submitting herewith copies of the references listed on the attached Form PTO-1449 (modified) for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

One attached document, U.S. Patent No. 6,245,364, is being submitted directly from the inventor. The other two attached documents, WO 95 26795 and GB 2 288552, were cited by the European Patent Office in an International Search Report of the corresponding PCT Application No. PCT/US00/14503 and relevance is indicated on the enclosed copy of the Search Report.

Additionally, Applicants wish to inform the Examiner of the existence of the following co-pending U.S. patent application which was filed with the U.S. Patent Office under Rule 371 as a national stage of PCT Application No. PCT/US00/14503:

U.S. Patent Application No. 09/979,667 filed November 26, 2001, in the name of Michael Martin, et al., entitled "Pharmaceutical Preparations of Bioactive Substances Extracted from Natural Sources."

07/18/2003 GCHAU1 00000003 031952 09578849

01 FC:1806 180.00 DA

VA-38778

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

This Supplemental Information Disclosure Statement is being submitted after the mailing of a non-final Office Action, but is believed to be prior to a final Office Action or a Notice of Allowance. Pursuant to 37 C.F.R. § 1.97(c)(2), it is believed that the fee for the submission of this Supplemental Information Disclosure Statement is \$180.00 as set forth in § 1.17(p). In the event any variance exists between the amount authorized and the Patent Office charges, please charge or credit any difference to the undersigned's Deposit Account No. 03-1952.

Respectfully submitted,

MORRISON & FOERSTER LLP

Dated: July 16, 2003

By: 

James Remenick

Registration No. 36,902

Customer Number 25227
Morrison & Foerster LLP
1650 Tysons Blvd., Suite 300
McLean, VA 22102
(703) 760-7700 (telephone)
(703) 760-7777 (facsimile)